...
search icon
ibio-img

iBio, Inc. Common Stock, Common Stock

IBIO

NAQ

$0.9145

-$0.07

(-7.11%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.56M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.78M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.94
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.64 L
$6.89 H
$0.9145

About iBio, Inc. Common Stock, Common Stock

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIBIOSectorS&P500
1-Week Return11.39%1.08%1.06%
1-Month Return18.26%1.11%6.17%
3-Month Return-83.49%-9.16%6.82%
6-Month Return-66.87%-7.29%-0.94%
1-Year Return-61.9%-8.72%11.83%
3-Year Return-99.41%5.18%49.19%
5-Year Return-99.88%30.45%86.63%
10-Year Return-99.98%81.41%188.21%

Financials

Jun '20Jun '21Jun '22Jun '23Jun '245YR TREND
Total Revenue1.64M2.37M2.38M50.00K225.00K[{"date":"2020-06-30","value":68.74,"profit":true},{"date":"2021-06-30","value":99.5,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":2.1,"profit":true},{"date":"2024-06-30","value":9.44,"profit":true}]
Cost of Revenue703.00K1.46M216.00K1.11M1.25M[{"date":"2020-06-30","value":48.08,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":14.77,"profit":true},{"date":"2023-06-30","value":75.65,"profit":true},{"date":"2024-06-30","value":85.5,"profit":true}]
Gross Profit935.00K909.00K2.17M50.00K225.00K[{"date":"2020-06-30","value":43.15,"profit":true},{"date":"2021-06-30","value":41.95,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":2.31,"profit":true},{"date":"2024-06-30","value":10.38,"profit":true}]
Gross Margin57.08%38.34%90.94%100.00%100.00%[{"date":"2020-06-30","value":57.08,"profit":true},{"date":"2021-06-30","value":38.34,"profit":true},{"date":"2022-06-30","value":90.94,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Operating Expenses15.64M32.02M51.86M29.34M16.86M[{"date":"2020-06-30","value":30.16,"profit":true},{"date":"2021-06-30","value":61.75,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":56.58,"profit":true},{"date":"2024-06-30","value":32.51,"profit":true}]
Operating Income(14.00M)(31.11M)(49.69M)(29.31M)(16.63M)[{"date":"2020-06-30","value":-1400300000,"profit":false},{"date":"2021-06-30","value":-3111100000,"profit":false},{"date":"2022-06-30","value":-4969000000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-1663400000,"profit":false}]
Total Non-Operating Income/Expense(4.89M)5.58M(1.05M)32.00K1.38M[{"date":"2020-06-30","value":-87.61,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-18.8,"profit":false},{"date":"2023-06-30","value":0.57,"profit":true},{"date":"2024-06-30","value":24.75,"profit":true}]
Pre-Tax Income(16.44M)(23.21M)(50.30M)(29.31M)(15.44M)[{"date":"2020-06-30","value":-1644400000,"profit":false},{"date":"2021-06-30","value":-2321300000,"profit":false},{"date":"2022-06-30","value":-5030400000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-1544300000,"profit":false}]
Income Taxes2.47M46.00K701.00K(1.20M)9.64M[{"date":"2020-06-30","value":25.64,"profit":true},{"date":"2021-06-30","value":0.48,"profit":true},{"date":"2022-06-30","value":7.27,"profit":true},{"date":"2023-06-30","value":-12.49,"profit":false},{"date":"2024-06-30","value":100,"profit":true}]
Income After Taxes(18.91M)(23.26M)(51.01M)(28.11M)(25.08M)[{"date":"2020-06-30","value":-1891500000,"profit":false},{"date":"2021-06-30","value":-2325900000,"profit":false},{"date":"2022-06-30","value":-5100500000,"profit":false},{"date":"2023-06-30","value":-2810700000,"profit":false},{"date":"2024-06-30","value":-2507900000,"profit":false}]
Income From Continuous Operations(16.44M)(23.21M)(50.30M)(29.31M)(15.44M)[{"date":"2020-06-30","value":-1644400000,"profit":false},{"date":"2021-06-30","value":-2321300000,"profit":false},{"date":"2022-06-30","value":-5030400000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-1544300000,"profit":false}]
Income From Discontinued Operations(20.79M)(20.79M)(20.79M)(35.70M)-[{"date":"2020-06-30","value":-2079100000,"profit":false},{"date":"2021-06-30","value":-2079100000,"profit":false},{"date":"2022-06-30","value":-2079100000,"profit":false},{"date":"2023-06-30","value":-3569900000,"profit":false},{"date":"2024-06-30","value":"-","profit":true}]
Net Income(18.91M)(23.26M)(51.01M)(29.31M)(24.91M)[{"date":"2020-06-30","value":-1891500000,"profit":false},{"date":"2021-06-30","value":-2325900000,"profit":false},{"date":"2022-06-30","value":-5100500000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-2490700000,"profit":false}]
EPS (Diluted)-(4.20)(5.71)(3.33)(6.42)[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":-420,"profit":false},{"date":"2022-06-30","value":-571,"profit":false},{"date":"2023-06-30","value":-333.32,"profit":false},{"date":"2024-06-30","value":-641.99,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IBIO
Cash Ratio 0.92
Current Ratio 1.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IBIO
ROA (LTM) -30.35%
ROE (LTM) -90.83%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IBIO
Debt Ratio Lower is generally better. Negative is bad. 0.40
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.60

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IBIO
Trailing PE NM
Forward PE NM
P/S (TTM) 43.38
P/B 1.33
Price/FCF NM
EV/R 37.07
EV/Ebitda NM
PEG NM

FAQs

What is iBio, Inc. Common Stock share price today?

iBio, Inc. Common Stock (IBIO) share price today is $0.9145

Can Indians buy iBio, Inc. Common Stock shares?

Yes, Indians can buy shares of iBio, Inc. Common Stock (IBIO) on Vested. To buy iBio, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IBIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of iBio, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of iBio, Inc. Common Stock (IBIO) via the Vested app. You can start investing in iBio, Inc. Common Stock (IBIO) with a minimum investment of $1.

How to invest in iBio, Inc. Common Stock shares from India?

You can invest in shares of iBio, Inc. Common Stock (IBIO) via Vested in three simple steps:

  • Click on Sign Up or Invest in IBIO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in iBio, Inc. Common Stock shares
What is iBio, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of iBio, Inc. Common Stock (IBIO) is $6.89. The 52-week low price of iBio, Inc. Common Stock (IBIO) is $0.64.

What is iBio, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of iBio, Inc. Common Stock (IBIO) is 1.33

What is the Market Cap of iBio, Inc. Common Stock?

The market capitalization of iBio, Inc. Common Stock (IBIO) is $13.56M

What is iBio, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of iBio, Inc. Common Stock is IBIO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top